Diabetic foot ulcers
~463M diabetics worldwide; up to 15% develop foot ulcers. ~6.5M US adults have a chronic wound each year.
Data & evidence
The case for therapeutic angiogenesis.
Millions of patients need better treatments, and public research shows angiogenic therapies can meaningfully improve healing. All figures below are drawn from cited public sources.
Epidemiology
Market & medical need
| Metric | Value | Source |
|---|---|---|
| Chronic wound patients (US, annual) | 6.5 million | Clinical literature |
| Diabetes prevalence (US) | 40.1 million (12% of population) | ADA report |
| Diabetics with foot ulcer (lifetime) | ~15% of diabetics | Okonkwo & DiPietro, 2017 |
| Global wound care market (2024) | $21.4 B | Research & Markets |
| Projected wound care market (2033) | $35.5 B | Research & Markets |
Evidence review
Preclinical & clinical evidence
| Therapy | Result | Model |
|---|---|---|
| Becaplermin (PDGF) | 23% closure vs 0% placebo at 16 weeks | Clinical, diabetic foot ulcer |
| VEGF-A topical | Faster diabetic wound closure | db/db mouse model |
| PDGF topical | Accelerated wound closure | db/db mouse model |
References available on request. Figures reflect publicly reported data and are presented for educational context, not as claims about our investigational programs.
Development focus
Target indications
Myocardial ischemia
Heart disease is the leading cause of death globally, with ~18M deaths per year.
Peripheral artery disease
Impaired limb perfusion affects an estimated 8.5M Americans.